We have located links that may give you full text access.
Feasibility and success of muscular ventricular septal defect occluders and mushroom-shaped occluders in transcatheter patent ductus arteriosus closure in low-weight children: a propensity score-matched retrospective analysis from a Chinese national regional health center.
Cardiology 2024 August 1
INTRODUCTION: Muscular ventricular septal defect occluders (MVSDO) have been attempted as an option in low-weight patients with patent ductus arteriosus (PDA). Few studies have assessed the safety of transcatheter patent ductus arteriosus closure (TCPC) using MVSDO. Therefore, we compared the outcomes in low-weight patients who used MVSDO and mushroom-shaped occluder (MSO).
METHODS: Medical records of children under 10 kg (n=417) who underwent TCPC from 2015 to 2021 at a Chinese health center were reviewed. They were divided into MSO (n=372) and MVSDO (n=45) groups. A 1:1 propensity score matching (PSM) was done considering gender, height, weight, body surface area (BSA), PDA diameter, and BSA-corrected PDA diameter.
RESULTS: All 45 children in the MVSDO group (mean weight: 5.92 ± 1.32 kg) achieved success immediate occlusion. One MVSDO migrated within 24 hours requiring unplanned surgery. MVSDO significantly ameliorated pulmonary artery hypertension. After PSM, each group comprised 41 children. The MVSDO group had a smaller effect on platelet counts (MVSDO vs. MSO =259.85 ± 114.82 vs. 356.12 ± 134.37, p < 0.001), a reduced incidence of thrombocytopenia (MVSDO vs. MSO = 2 vs. 7, p = 0.001), and a higher rate of residual shunting (MVSDO vs. MSO =16/41 vs. 5/41, p = 0.005), compared with the MSO group. Thrombocytopenia resolved during hospitalization and micro-shunts disappeared by six months. No pulmonary artery or descending aortic secondary stenosis was observed in one-year follow-up.
CONCLUSIONS: MVSDO using in low-weight children is feasible, with high success and satisfactory postoperative and short-term follow-up outcomes, including lower thrombocytopenia incidence, compared to MSO. Further long-term studies with larger samples are recommended.
METHODS: Medical records of children under 10 kg (n=417) who underwent TCPC from 2015 to 2021 at a Chinese health center were reviewed. They were divided into MSO (n=372) and MVSDO (n=45) groups. A 1:1 propensity score matching (PSM) was done considering gender, height, weight, body surface area (BSA), PDA diameter, and BSA-corrected PDA diameter.
RESULTS: All 45 children in the MVSDO group (mean weight: 5.92 ± 1.32 kg) achieved success immediate occlusion. One MVSDO migrated within 24 hours requiring unplanned surgery. MVSDO significantly ameliorated pulmonary artery hypertension. After PSM, each group comprised 41 children. The MVSDO group had a smaller effect on platelet counts (MVSDO vs. MSO =259.85 ± 114.82 vs. 356.12 ± 134.37, p < 0.001), a reduced incidence of thrombocytopenia (MVSDO vs. MSO = 2 vs. 7, p = 0.001), and a higher rate of residual shunting (MVSDO vs. MSO =16/41 vs. 5/41, p = 0.005), compared with the MSO group. Thrombocytopenia resolved during hospitalization and micro-shunts disappeared by six months. No pulmonary artery or descending aortic secondary stenosis was observed in one-year follow-up.
CONCLUSIONS: MVSDO using in low-weight children is feasible, with high success and satisfactory postoperative and short-term follow-up outcomes, including lower thrombocytopenia incidence, compared to MSO. Further long-term studies with larger samples are recommended.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app